Mustang Bio, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2026

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

Note 4 - Accounts Payable and Accrued Expenses

At March 31, 2026, and December 31, 2025, accounts payable and accrued expenses consisted of the following:


	March 31,		December 31,
($ in thousands)	2026		2025
Accounts payable	$	3,341	$	3,510
Accrued research and development		273		250
Accrued compensation		160		24
Other⁽¹⁾		1,541		1,627
Total accounts payable and accrued expenses	$	5,315	$	5,411

(1) Includes approximately $1.3 million of accrued consideration, including approximately $50,000 of accrued interest, related to the repurchase of assets from uBriGene (Boston) Biosciences, Inc. (“uBriGene”) in 2024. The asset repurchase consisted of purchase consideration of an upfront payment of $0.1 million, and a deferred amount of approximately $1.3 million due twelve months after closing; however, the Company can elect to delay its payment obligation for the deferred amount for additional 6 month periods, upon written notice to uBriGene, if the Company’s net assets are below $20 million. Additionally, beginning in June 2025, the deferred amount began accruing interest at a rate of 5% per annum. In December 2025, the Company’s net assets were below $20 million, and it elected to delay the payment.